| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.6 |